(A) Outline describing the steps for building the DNA methylation classifier. In a first step, 200 randomly selected patients were used to identify HELP probe sets that best predicted survival. The model was then tested on a different cohort of 95 patients (test set). Once the final model was selected, its performance in predicting survival was tested in an independent validation set consisting of 49 randomly selected cases.
(B) Kaplan-Meier curves for overall survival for the predicted groups in the independent validation set. Overall survival was compared between patients in an independent validation set that were predicted either alive or deceased by the DNA methylation classifier. (Cox proportional hazards p < 0.005, hazard ratio = 1.39, 95% CI = 1.10, 1.75).
(C) Kaplan-Meier curves for event-free survival for the predicted groups in the independent validation set. Event-free survival was compared between patients in an independent validation set that were predicted either alive or deceased by the DNA methylation classifier (Cox proportional hazards p < 0.0002, hazard ratio: 1.53, 95% CI = 1.21, 1.93).
(D) Kaplan-Meier curves for overall survival for the predicted groups in the combined test and independent validation sets. Overall survival was compared between patients in the combined test and independent validation sets that were predicted either alive or deceased by the DNA methylation classifier. (Cox Proportional hazards p < 0.000003, hazard ratio: 1.34, 95% CI = 1.18, 1.51).
(E) Multivariate Cox proportional hazards regression model for the DNA methylation predictor, age, cytogenetic risk, NPM1 mutation, FLT3-ITD and CEBPA mutations. For additional information please see , as well as supplementary R scripts.